Study of KC1036 for teens with advanced Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 to under 18 years old
- Diagnosed with Ewing sarcoma (a cancer of bone or soft tissue) that has spread or not responded to standard therapy
- Weight at least 30 kg (66 pounds)
- Able to perform daily activities with minimal help (performance score 60% or higher)
- Have at least one tumor that can be measured on scans
- No prior treatment with a specific type of targeted drug called a VEGFR-TKI
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving radiation therapy before surgery to treat Ewing sarcoma, a bone cancer that's hard to remove completely. The goal is to shrink the tumor first, then remove it surgically, to improve outcomes for patients with high-risk disease.
This study is testing whether a blood test called ProGRP can help doctors see how well treatment is working in people with Ewing sarcoma. If you are newly diagnosed and are about to start your first treatment, this study may help improve how we track your progress.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.